Cyproheptadine in treatment of chronic schizophrenia: A double-blind, placebo-controlled study

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 1, 1999, Pages 49-52

  Akhondzadeh, S ^a   Mohammadi, M R ^a   Amini Nooshabadi, H ^a   Davari Ashtiani, R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROHEPTADINE; HALOPERIDOL; SEROTONIN RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CYPROHEPTADINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0032907201     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00197.x     Document Type: Article

References (22)

1. 1. Jablensky A, Sartorius N, Ernberg G. (1991) Schizophrenia: manifestation, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine, 20(Suppl.), 1-97.
2. 2. Anderson NC, Olsen SA. (1982) Negative vs. positive schizophrenia. Definition and Validation Archives of General Psychiatry, 39, 789-794.
3. 3. Arndt S, Allinger RJ, Anderson NC. (1991) The distinction of positive and negative symptoms. The failure of a two dimensional model. British Journal of Psychiatry, 158, 317-322.
4. 2 neurotransmission as revealed by selective antagonism of hyperactivity to tryptamine and apomorphine. Journal of Pharmaceutical and Experimental Therapeutics, 254, 945-951.
5. 2) receptor binding in the frontal cortex of schizophrenic patients. Journal of Neural Transmission General Sec, 85, 19-29.
6. 6. Breier A. (1995) Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia Research, 14, 187-202.
7. 7. Bleich A, Brown SL, Kahn R, (1988) The role of serotonin in schizophrenia. Schizophrenia Bulletin, 14, 297-315.
8. 8. Breier A, Wolkowitz OM, Doran AR. (1987) Neuroleptic responsivity of negative and positive symptoms in schizophrenia. American Journal of Psychiatry, 144, 1549-1555.
9. 9. Breier A, Kirkpatrick B, Buchanan RW. (1993) Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia. Biological Psychiatry, 34, 492-494.
10. 10. Fuller RW. (1992) Basic advances in serotonin pharmacology. Journal of Clinical Psychiatry, Suppl. 10 (53), 3645.
11. 11. Boses FC, Martin IL. (1994) Molecular biology of 5-HT receptors. Neuropharmacology, 33, 275-317.
12. 12. Baxter G, Kennett G, Blaney F. (1995) 5-HT2 receptor subtypes: a family re-united? Trends in Pharmacological Science, 16, 105-109.
13. 13. Peroutka SJ. (1995) 5-HT receptors: past, present and future. Trends in Neuroscience, 18, 68-69.
14. 14. American Psychiatric Association. (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (DSM IV). American Psychiatric Press, Washington, DC.
15. 15. Kay SR, Fiszbein A, Opler LA. (1987) The Positive and Negative Syndrome Scale for Schizophrenia. Schizophrenia Bulletin, 13, 261-276.
16. 16. Kane JM, Mayerhoff D. (1989) Do negative symptoms respond to pharmacological treatment? British Journal of Psychiatry, 155, 115-118.
17. 17. Meltzer HY, Zureick J. (1989) Negative symptoms in schizophrenia: a target for new drug development. In: Dahl SG, Gram LF, eds. Clinical Pharmacology in Psychiatry. Heidelberg: Springer-Verlag, 68-77.
18. 18. Nasrallah HA, Risch SC, Flowler RC. (1979) Reserpine, serotonin and schizophrenia [Letter]. American Journal of Psychiatry, 136, 856-857.
19. 19. Breier A, Buchanan RW, Kirkpatrik B. (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry, 151, 20-26.
20. 20. Silver H, Blacker M, Weller MPI, Lerer B. (1989) Treatment of chronic schizophrenia with cyproheptadine. Biological Psychiatry, 25, 502-504.
21. 21. Silver H, Blacker M, Weller MPI, Lerer B. (1991) Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study. Biological Psychiatry, 39, 523-525.
22. 22. Cohen A. (1992) Fluoxetine induced yawning and anorgasmia reversed by cyproheptadine treatment [letter]. Journal of Clinical Psychiatry, 53, 174.